{"nctId":"NCT00699153","briefTitle":"Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","startDateStruct":{"date":"2008-06"},"conditions":["Ocular Inflammation"],"count":400,"armGroups":[{"label":"Loteprednol Etabonate","type":"EXPERIMENTAL","interventionNames":["Drug: Loteprednol Etabonate"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of Ophthalmic Loteprednol Etabonate"]}],"interventions":[{"name":"Loteprednol Etabonate","otherNames":[]},{"name":"Vehicle of Ophthalmic Loteprednol Etabonate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects at least 18 years of age\n* Subjects who have the ability to understand and sign an informed consent form and provide Health Insurance Portability and Accountability Act (HIPAA) authorization.\n* Subjects who are candidate for routine, uncomplicated cataract surgery.\n* Subjects who are not of childbearing potential or subjects who have a negative urine pregnancy test result at screening.\n* Subjects must be willing and able to comply with all treatment and follow- up procedures.\n\nExclusion Criteria:\n\n* Subjects who have known hypersensitivity or contraindication to the study drug or its components.\n* Subjects who have a history or presence of chronic generalized systemic disease that the investigator feels might increase the risk to the subject or compound the result of the study.\n* Subjects who have a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up.\n* Subjects with elevated intraocular pressure (\\>/= 21 mm Hg), uncontrolled glaucoma, or being treated for glaucoma in the study eye.\n* Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the non-study eye.\n* Subjects who have had ocular surgery in the study eye within 3 months or in the fellow eye within 2 weeks prior to the screening visit.\n* Women who are pregnant or breast feeding.\n* Subjects who have participated in an investigational drug or device study within the last 30 days.\n* Subjects previously randomized in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0","description":"A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \\>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With Grade 0 (no) Pain","description":"Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Complete Resolution of Anterior Chamber Cells and Flare, at Each Visit.","description":"A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \\>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare","description":"A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= \\>30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.20"},{"groupId":"OG001","value":"-0.6","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"1.51"},{"groupId":"OG001","value":"-0.8","spread":"1.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"1.58"},{"groupId":"OG001","value":"-1.1","spread":"1.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"1.59"},{"groupId":"OG001","value":"-1.1","spread":"2.01"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":204},"commonTop":["Anterior chamber inflammation","Eye Pain","Corneal Edema","Conjunctival Hyperemia","Ciliary Hyperemia"]}}}